Arş. Gör. Maral Martin MILDANOĞLU

1. Revisiting Platinum Sensitivity in Relapsed Small-Cell Lung Cancer: Outcomes of Platinum-Containing Doublet Chemotherapy in the 3-6 Month Relapse Window.

Çil İ., Mıldanoğlu M. M., Kutlu Y., Güren A. K., Sarı M., Ökten İ. N., et al.

Current oncology (Toronto, Ont.) , cilt.33, sa.8, 2026 (SCI-Expanded, Scopus)

2. Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501).

Akkus E., Kayaalp M., Ergözoğlu M. A., Koç Kuş I., Bayram D., Kılıçtaş B., et al.

International journal of cancer , 2026 (SCI-Expanded, Scopus)

3. Real-world outcomes of trifluridine/tipiracil with or without bevacizumab in refractory metastatic colorectal cancer: a multicenter cohort study from Turkey.

Bayram S., Koylu B., Mildanoglu M. M., Demir B., Arvas H., Guven O. D., et al.

Discover oncology , cilt.17, sa.1, 2026 (SCI-Expanded) Sürdürülebilir Kalkınma

4. Prognostic Impact of ABO/Rh Blood Group-Systemic Inflammation Indices Interactions in Small-Cell Lung Cancer.

Yıldız A., ZENGİN B. A., Mildanoglu M. M., ULUFER B., BİLİCİ A., AK N.

Biomedicines , cilt.14, sa.5, 2026 (SCI-Expanded, Scopus)

5. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score.

Sünger E., Muğlu H., Yücel M. H., Engin Delipoyraz E., Mıldanoğlu M. M., Özçelik H., et al.

Journal of clinical medicine , cilt.15, sa.8, 2026 (SCI-Expanded, Scopus)

6. Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.

Bayram S., Köylü B., Mıldanoğlu M. M., Alemdar M. S., Yerlikaya T., Selçukbiricik F., et al.

Current oncology (Toronto, Ont.) , cilt.33, sa.4, 2026 (SCI-Expanded, Scopus)

7. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.

Mıldanoğlu M. M., Kemik F., Eryaşar M., ÖZÇELİK H., SÜNGER E., Yücel M. H., et al.

Pharmaceuticals (Basel, Switzerland) , cilt.19, sa.4, 2026 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

8. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study.

Mildanoglu M. M., Yucel M. H., Engin Delipoyraz E., SÜNGER E., ÖZÇELİK H., FİDAN S., et al.

Journal of clinical medicine , cilt.15, sa.6, 2026 (SCI-Expanded, Scopus)

9. Prognostic Significance of Frailty in Liver Cirrhosis Patients: A Prospective Single-Center Study.

Mıldanoğlu M. M., Akpınar A., Koçhan K., BİLİCİ A., Biberci Keskin E., ŞENTÜRK H.

Journal of clinical medicine , cilt.15, sa.5, 2026 (SCI-Expanded, Scopus)

10. Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO).

Akkus E., Kayaalp M., Ergözoğlu M. A., Koç Kuş I., Bayram D., Kılıçtaş B., et al.

JCO global oncology , cilt.12, sa.3, 2026 (ESCI, Scopus)

11. Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study

MILDANOĞLU M. M., Kutlu Y., BAŞ O., Koylu B., Dae S. A., SAKİN A., et al.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

12. Cytotoxic Lesion of the Corpus Callosum Associated with 5-Fluorouracil: A Case Report and Review of Literature

MILDANOĞLU M. M., KARAALİOĞLU B., Engi̇N Deli̇Poyraz E., YÜCEL M. H., Ölmez Ö. F.

Journal of Oncological Science , cilt.11, sa.2, ss.179-181, 2025 (Scopus, TRDizin)

13. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG).

majıdova n., Yaslikaya S., Mildanoğlu M. M., Coşkun A., Uzundal D. E., Sahin T. K., et al.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.36, sa.5, ss.293-301, 2025 (SCI-Expanded, Scopus, TRDizin)

14. Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: tek merkez deneyimi

Muglu H., Sünger E., YÜCEL M. H., Mildanoğlu M. M., Delipoyraz E. E., J., et al.

Ege Tıp Dergisi , cilt.64, sa.1, ss.71-76, 2025 (TRDizin)

15. An Unusual Case of Metastatic Gastric Cancer Presenting with Right Heart Failure and Cardiac Metastasis

Engin Delipoyraz E., MILDANOĞLU M. M., SÜRÜL B., OLMUŞÇELİK O., ERKANLI K., BİLİCİ A.

Medicina (Lithuania) , cilt.61, sa.2, 2025 (SCI-Expanded, Scopus)

Arş. Gör. Maral Martin MILDANOĞLU

Yayınlar & Eserler

1. Revisiting Platinum Sensitivity in Relapsed Small-Cell Lung Cancer: Outcomes of Platinum-Containing Doublet Chemotherapy in the 3-6 Month Relapse Window.

2. Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501).

3. Real-world outcomes of trifluridine/tipiracil with or without bevacizumab in refractory metastatic colorectal cancer: a multicenter cohort study from Turkey.

4. Prognostic Impact of ABO/Rh Blood Group-Systemic Inflammation Indices Interactions in Small-Cell Lung Cancer.

5. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score.

6. Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.

7. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.

8. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study.

9. Prognostic Significance of Frailty in Liver Cirrhosis Patients: A Prospective Single-Center Study.

10. Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO).

11. Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study

12. Cytotoxic Lesion of the Corpus Callosum Associated with 5-Fluorouracil: A Case Report and Review of Literature

13. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG).

14. Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: tek merkez deneyimi

15. An Unusual Case of Metastatic Gastric Cancer Presenting with Right Heart Failure and Cardiac Metastasis

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (Scopus)

H-İndeks (Scopus)

Tez Danışmanlığı

Açık Erişim